相关实验视频
Updated: Jun 14, 2025

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
94.3K
使用葡萄糖调节系统计算模型对葡萄糖反应性葡萄糖治疗方法的分析
Ali A Alizadehmojarad1, Sungyun Yang1, Xun Gong1
1Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Advanced healthcare materials
|August 29, 2024
概括
葡萄糖反应性葡萄糖 (GRG) 疗法在糖尿病治疗中显示出前景. 目前的模型需要大幅改进,以准确预测GRG的性能,并改善患者的葡萄糖调节.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 计算生物学 计算生物学
背景情况:
- 葡萄糖反应性葡萄糖 (GRG) 疗法为治疗糖尿病和预防低血糖症提供了一种新的方法.
- 现有的GRG设计需要在生理学上严格评估,以评估其治疗潜力.
研究的目的:
- 使用计算建模评估和比较两个不同的GRG设计 (GRG-I和GRG-II) 的性能.
- 通过将它们的动力学整合到生理糖调节模型中,预测GRG的疗效.
主要方法:
- 使用多分区葡萄糖调节模型 (IMPACT) 来模拟GRG的性能.
- 将模型预测与来自老鼠和小鼠的体内实验数据进行比较.
- 模型治疗性胰岛素和葡萄糖输液用于1型糖尿病 (T1DM) 的人类受试者.
主要成果:
- 与体内数据相比,GRG-I的性能被高估了41.5%±14%,而GRG-II被低估了24.8%±16%.
- 显著的差异突显出需要改进葡萄糖激素动态的计算模型.
- 对T1DM受试者的模型模拟表明需要进一步改进.
结论:
- 目前的计算模型需要大量的改进,以准确地捕捉临床环境中的同时胰岛素,葡萄糖和葡萄糖激素动态.
- 进一步开发GRG技术需要改进生理学和非生理学建模方法.
- 增强的建模对于GRG疗法的成功临床转化至关重要.
相关概念视频
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Hypoglycemia and Glucagon
217
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
217
Hormones Regulating Blood Glucose
3.2K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.2K
Glucose Homeostasis: Regulation of Blood Glucose
1.5K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.5K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides
148
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
148

